

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Michael Buschle and Karen Lingnau

Serial No.: 10/550,820

Filed: September 23, 2005

For: USE OF ALUM AND A TH1 IMMUNE  
RESPONSE INDUCING ADJUVANT  
FOR ENHANCING IMMUNE RESPONSE

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: SONN:077US

Confirmation No.: 8341

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being  
electronically filed with the United States Patent and  
Trademark Office via EFS-Web on the date below:

May 11, 2007

Date

Mark B. Wilson

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/SONN:077US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'MBW', is written over the typed name.

Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: May 11, 2007

Form PTO-1449 (modified)	Atty. Docket No.: SONN:077US	Serial No.: 10/550,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant: Michael Buschle Karen Lingnau	
	Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C90	Aichinger <i>et al.</i> , "Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins," <i>J. Biol. Chem.</i> , 272:29127-29136, 1997.
	C91	Bihl <i>et al.</i> , "Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses," <i>J. Immunol.</i> , 176:4094-4101, 2006.
	C92	Brooks <i>et al.</i> , "HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex," <i>J. Immunol.</i> , 161:5252-5259, 1998.
	C93	Field, "Human cytomegalovirus: challenges, opportunities and new drug development," <i>Antiviral Chem. Chemotherapy</i> , 10:219-232, 1999.
	C94	Fowler <i>et al.</i> , "The outcome of congenital cytomegalovirus infection in relation to maternal antibody status," <i>New Engl. J. Med.</i> , 326:663-673, 1992.
	C95	Gallot <i>et al.</i> , "Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination," <i>J. Immunol.</i> , 167:4196-4206, 2001.
	C96	Gavin <i>et al.</i> , "Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes," <i>J. Immunol.</i> , 151:3971-3980, 1993.

25775694.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: SONN:077US	Serial No.: 10/550,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Michael Buschle Karen Lingnau	
		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-3	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C97	Gorga <i>et al.</i> , "Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line," <i>J. Biol. Chem.</i> , 262:16087-16094, 1987.
	C98	Greenberg and Riddell, "Deficient Cellular Immunity- Finding and Fixing the Defects," <i>Science</i> , 285:546-551, 1999.
	C99	Khattab <i>et al.</i> , "Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes," <i>J. Med. Virol.</i> , 52:68-76, 1997.
	C100	Kronenberg <i>et al.</i> , "Conserved lipid and peptide presentation functions of nonclassical class I molecules," <i>Immunol. Today</i> , 20:515-521, 1999.
	C101	Kuzushima <i>et al.</i> , "Efficient Identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay," <i>Blood</i> , 98:1872-1880, 2001.
	C102	Lalvani <i>et al.</i> , "Rapid effector function in CD8+ memory T cells," <i>J. Exp. Med.</i> , 186:859-865, 1997.
	C103	Lamas <i>et al.</i> , "Relationship between peptide binding and T cell epitope selection: a study with subtypes of HLA-B27," <i>Int. Immunol.</i> , 10:259-266, 1998.
	C104	Levitsky <i>et al.</i> , "Supermotif Peptide Binding and Degeneracy of MHC: Peptide Recognition in an EBV Peptide-Specific CTL Response with Highly Restricted TCR Usage," <i>Human Immunol.</i> , 61:972-984, 2000.
	C105	Masuoka <i>et al.</i> , "Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes," <i>Viral Immunology</i> , 14:369-377, 2001.
	C106	McLaughlin-Taylor <i>et al.</i> , "Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes," <i>J. Med. Virol.</i> , 43:103-110, 1994.
	C107	Nichols and Boeckh, "Recent advances in the therapy and prevention of CMV infections," <i>J. Clin. Virol.</i> , 16:25-40, 2000.
	C108	Nijman <i>et al.</i> , "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> , 6:1215-1219, 1993.

25775694.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: SONN:077US	Serial No.: 10/550,820
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Michael Buschle Karen Lingnau	
		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C109	Retriere <i>et al.</i> , "Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response," <i>J. Virol.</i> , 74:3948-3952, 2000.
	C110	Saulquin <i>et al.</i> , "A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening," <i>Eur. J. Immunol.</i> , 30:2531-2539, 2000.
	C111	Sia and Patel, "New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients," <i>Clin. Microbiol. Rev.</i> , 13:83-121, 2000.
	C112	Solache <i>et al.</i> , "Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus," <i>J. Immunol.</i> , 163:5512-5518, 1999.
	C113	Tynan <i>et al.</i> , "The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation," <i>J. Exp. Med.</i> , 202:1249-1260, 2005.
	C114	Udaka <i>et al.</i> , "Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries," <i>J. Exp. Med.</i> , 181:2097-2108, 1995.
	C115	Valli <i>et al.</i> , "Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients," <i>J. Clin. Invest.</i> , 91:616-628, 1993.
	C116	Von Son <i>et al.</i> , "Overcoming the problem of cytomegalovirus infection after organ transplantation: calling for Heracles?," <i>Intervirology</i> , 42:285-290, 1999.

25775694.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.